Lean Hogs (LH)

Labcorp Hldgs (NYSE:LH) Stock

Labcorp Holdings

Labcorp Hldgs

Laboratory Corp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

Labcorp Holdings Inc

LINKHOME HLDGS INC COM

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

Lianhe Sowell International Group Ltd - Ordinary Shares

Lianhe Sowell International Group Ltd

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

News

Laboratory Corporation Of America Holdings

Labcorp Expands Oncology Portfolio With New Tests For Solid And Blood Cancers; Reveals Expansion Of Capabilities To OmniSeq INSIGHT

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $274 to $290.

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Labcorp Hldgs, Raises Price Target to $290

Ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Labcorp Hldgs and provided 12-month price targets. The average target is $269.7, accompanied by a high estimate of $300.00 and a low estimate of $240.00. Observing a 4.0% increase, the current average has risen from the previous average price target of $259.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1746554439_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Labcorp Hldgs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$274.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Labcorp Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Delving into Labcorp Hldgs's Background</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Understanding the Numbers: Labcorp Hldgs's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Labcorp Hldgs's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.3%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin is impressive, surpassing industry averages. With a net margin of 6.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Hldgs's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.6%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.18%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.78, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Labcorp Hldgs's Future

Piper Sandler analyst David Westenberg maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $260 to $280.

Piper Sandler Maintains Neutral on Labcorp Hldgs, Raises Price Target to $280

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $240 to $250.

Barclays Maintains Equal-Weight on Labcorp Hldgs, Raises Price Target to $250

Baird analyst Eric Coldwell maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $253 to $267.

Baird Maintains Outperform on Labcorp Hldgs, Raises Price Target to $267

Wall Street rose modestly by midday Tuesday, as investors weighed the latest developments in trade negotiations and awaited a wave of key economic data and corporate earnings set for <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">release later this week.</a>
President Donald Trump is <a href="https://apnews.com/article/trump-tariffs-automakers-factories-relief-25a400c98e02c01c8c54502384e267e1">expected</a> to unveil a new executive order on auto tariffs later today. Meanwhile, U.S. Treasury Secretary Bessent added that the administration is pursuing bilateral trade agreements with 17 major partners, excluding China.
The S&amp;P 500 climbed 0.4%, putting it on track for a sixth consecutive gain—its longest winning streak since November 2024.
In the bond market, U.S. Treasuries extended their rally, with yields falling for a sixth straight session. The yield on the 10-year benchmark dropped to 4.17%, marking a two-week low.
Gold prices slipped 0.6% to $3,325 per ounce, while WTI crude oil futures fell 2.4% to $60 per barrel, the lowest level in two weeks. Oil prices are under pressure from escalating global trade tensions and weaker U.S. economic data, and crude is now on track for a 15% decline in April—its steepest monthly drop since 2021.
Bitcoin traded little changed, around $95,000.
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,513.32</td>
<td>+285.73</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,548.89</td>
<td>+20.14</td>
<td>0.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,468.38</td>
<td>+41.09</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,969.38</td>
<td>+3.83</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.4% up to $552.91.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.7% to $404.9.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;edged 0.3% higher to $473.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.5% to $195.96.</li>
<li>The&nbsp;Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 0.8%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks moving on earnings report included:
<ul>
<li>Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>): down 0.6%</li>
<li>Cadence Design Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>): up 4.0%</li>
<li>Brown &amp; Brown, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>): down 6.3%</li>
<li>Nucor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>): up 0.9%</li>
<li>F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>): down 0.9%</li>
<li>Alexandria Real Estate Equities Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>): down 6.7%</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>): down 1.0%</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 2.7%</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>): up 5.0%</li>
<li>American Tower Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>): up 4.3%</li>
<li>Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>): up 5.2%</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>): down 7.7%</li>
<li>Zebra Technologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>): up 6.1%</li>
<li>Ecolab, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 2.2%</li>
<li>Hilton Worldwide Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>): up 1.6%</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>): up 2.3%</li>
<li>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>): down 1.6%</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>): down 0.5%</li>
<li>General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>): down 0.7%</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): up 1.9%</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>): up 4.4%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 0.8%</li>
<li>Sysco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>): up 0.4%</li>
<li>Xylem Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>): up 1.5%</li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>): up 1.5%</li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>): up 0.7%</li>
<li>Corning, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>): up 2.5%</li>
<li>Paccar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>): down 3.0%</li>
<li>A.O. Smith Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>): up 4.0%</li>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>): up 0.5%</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): down 1.4%</li>
</ul>
Stocks slated to report earnings after the bell include Arch Capital Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Caesars Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>), Veralto Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>), Seagate Technology Holdings PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>), Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), Extendicare Inc. (TSE: EXE), Fair Isaac Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Boston Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>), PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>), Extra Space Storage Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>), Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>), ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>), First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), Regency Centers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REG#NASDAQ">REG</a>), Essex Property Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>), and Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>).
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Economics

ETFs

ACGL

BKNG

CDNS

CSGP

SPDR Dow Jones Industrial Average ETF Trust

FFIV

FICO

FSLR

INCY

MDLZ

PCAR

PYPL

REGN

SBUX

SPGI

VLTO

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday?

<ul>
<li>Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS:
<ul>
<li>Revenue guidance of 6.7% to 8.0%</li>
<li>Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05</li>
<li>Free Cash Flow of $1.10 billion to $1.25 billion</li>
</ul>
</li>
</ul>

Guidance

Labcorp Raises FY25 Adj EPS Guidance From $15.60-$16.40 To $15.70-$16.40 Vs $17.59 Estimate; Reaffirms Sales Guidance Of $13.88B-$14.05B Vs $14.58B Estimate

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.84 per share which missed the analyst consensus estimate of $4.17 by 7.91 percent. This is a 4.35 percent increase over earnings of $3.68 per share from the same period last year. The company reported quarterly sales of $3.35 billion which missed the analyst consensus estimate of $3.48 billion by 3.93 percent. This is a 5.29 percent increase over sales of $3.18 billion the same period last year.

Earnings

Earnings Misses

Laboratory Corp Q1 Adj. EPS $3.84 Misses $4.17 Estimate, Sales $3.35B Miss $3.48B Estimate

AEYE

AMSF

APAM

ARCB

ARCC

ASTE

ASTL

ATRC

BBIO

BBVA

BGFV

BRSP

CECO

CHCT

CLVT

CVLT

DHIL

ENSG

ENVA

ESRT

ETWO

EXLS

FELE

FFIC

FIBK

FOUR

FRSH

FRST

FYBR

HLMN

HOUS

HRZN

HSBC

HURN

ILPT

INTZ

JAKK

JBGS

JBLU

KNSA

LFUS

LGIH

LOGI

LXFR

Earnings Scheduled For April 29, 2025

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Laboratory Corp will report an earnings per share (EPS) of $3.73. 
Anticipation surrounds Laboratory Corp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 0.59% drop in the share price the following trading session.
Here's a look at Laboratory Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.39</td>
<td>3.49</td>
<td>3.78</td>
<td>3.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.45</td>
<td>3.50</td>
<td>3.94</td>
<td>3.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856181_0.png" alt="eps graph" />
<h3>Performance of Laboratory Corp Shares</h3>
Shares of Laboratory Corp were trading at $228.31 as of April 25. Over the last 52-week period, shares are up 13.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Laboratory Corp</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Laboratory Corp.
The consensus rating for Laboratory Corp is Buy, derived from 9 analyst ratings. An average one-year price target of $273.0 implies a potential 19.57% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Quest Diagnostics, DaVita and Chemed, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Quest Diagnostics, with an average 1-year price target of $183.86, suggesting a potential 19.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DaVita, with an average 1-year price target of $169.0, suggesting a potential 25.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $670.5, suggesting a potential 193.68% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Quest Diagnostics, DaVita and Chemed, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labcorp Hldgs</td>
<td>Buy</td>
<td>9.76%</td>
<td>$896.30M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>12.09%</td>
<td>$863M</td>
<td>3.20%</td>
</tr>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>1.09%</td>
<td>$234.12M</td>
<td>6.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Laboratory Corp ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the lowest return on equity compared to the other companies analyzed.
<h3>Get to Know Laboratory Corp Better</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Laboratory Corp's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Laboratory Corp showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Laboratory Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Laboratory Corp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.77%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Laboratory Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.78%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LH/earnings">To track all earnings releases for Laboratory Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Laboratory Corp

Labcorp Announced Today The Expansion Of Its Precision Oncology Portfolio With Two Solutions

Acquisition aims to provide broader access to comprehensive testing and laboratory services for patients and physicians in North Mississippi &nbsp;
BURLINGTON, N.C. (April 21, 2025) –&nbsp;<a href="https://www.labcorp.com/">Labcorp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>),&nbsp;a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services' ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories. &nbsp; Through this acquisition, North Mississippi Health Services' patients and providers will have continuity of high-quality laboratory services and access to Labcorp's leading clinical laboratory services, robust data and digital tools.&nbsp;In addition, Labcorp will open three new patient service centers in Tupelo, West Point and Amory by mid-year to increase availability of laboratory services in North Mississippi.&nbsp;

Reported April 18, 2025: Labcorp Acquires Select Assets Of North Mississippi Health Services' Ambulatory Outreach Laboratory Business; No Financial Terms Disclosed

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $285 to $274.

Truist Securities Maintains Buy on Labcorp Hldgs, Lowers Price Target to $274

Barclays analyst Jack Meehan maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $260 to $240.

Barclays Maintains Equal-Weight on Labcorp Hldgs, Lowers Price Target to $240

In the latest quarter, 8 analysts provided ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.0, with a high estimate of $300.00 and a low estimate of $260.00. This current average has increased by 5.11% from the previous average price target of $262.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631264_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Labcorp Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Get to Know Labcorp Hldgs Better</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Hldgs showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Labcorp Hldgs: Insights From 8 Financial Analysts

Redburn Atlantic analyst Jamie Clark initiates coverage on Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy rating and announces Price Target of $276.

Initiation

Redburn Atlantic Initiates Coverage On Labcorp Hldgs with Buy Rating, Announces Price Target of $276

Labcorp Reveals Nationwide Launch Of pTau-217/Beta Amyloid 42 Ratio, New Blood-based Biomarker Test To Aid In Diagnosis Of Alzheimer's Disease

Health Care

General

Labcorp Will Acquire Select Assets Of Bioreference Health, A Wholly Owned Subsidiary Of Opko Health For $225M, Including $192.5M Payable At Closing And Up To $32.5M In An Earnout Based On Performance

10 analysts have shared their evaluations of Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.8, a high estimate of $300.00, and a low estimate of $260.00. Witnessing a positive shift, the current average has risen by 4.8% from the previous average price target of $262.22.
<img src="https://www.benzinga.com/files/images/story/2025/1741089659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Labcorp Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Labcorp Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Labcorp Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>About Labcorp Hldgs</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Insights: Labcorp Hldgs</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Labcorp Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.76%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.78% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Labcorp Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About Labcorp Hldgs

Press Releases

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Labcorp to Announce First Quarter Financial Results on April 29, 2025

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Dividends

Labcorp Declares Quarterly Dividend

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Labcorp Announces 2025 First Quarter Results

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Hldgs

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL